Hepatic arterial embolization for unresectable hepatocellular carcinomas: Do technical factors affect prognosis?

Japanese Journal of Radiology

Volumn 30, Issue 7, 2012, Pages 560-566

  Yamakado, Koichiro ^a   Miyayama, Shiro ^b   Hirota, Shozo ^c   Mizunuma, Kimiyoshi ^d   Nakamura, Kenji ^e   Inaba, Yoshitaka ^f   Maeda, Akihiro ^c   Matsuo, Kunihiro ^g   Nishida, Norifumi ^h   Aramaki, Takeshi ⁱ   Anai, Hiroshi ^j   Koura, Shinichi ^k   Oikawa, Shigeo ^l   Watanabe, Ken ^m   Yasumoto, Taku ⁿ   Furuichi, Kinya ^o   Yamaguchi, Masato ^p  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NASU RED CROSS HOSPITAL   (Japan)

^e Daito Central Hospital   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g Narumi Hospital   (Japan)

^h Osaka Prefecture University   (Japan)

ⁱ SHIZUOKA CANCER CENTER   (Japan)

^j NARA MEDICAL UNIVERSITY   (Japan)

^k FUKUOKA UNIVERSITY   (Japan)

^l Iwate Prefectural Central Hospital   (Japan)

^m JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^o Higashiosaka City General Hospital   (Japan)

^p KOBE UNIVERSITY   (Japan)

more..

Author keywords

Arterial embolization; Hepatocellular carcinoma; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BILOMA; CANCER INVASION; CANCER PROGNOSIS; CHOLANGITIS; FEMALE; HUMAN; INFARCTION; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER INFARCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; FEMALE; HEPATIC ARTERY; HUMANS; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84866008337     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-012-0088-1     Document Type: Article

References (27)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
2. CammàC, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47-54.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-42.
4. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734-1739.
5. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
6. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer. 1991;68:2150-2154.
7. Shim JH, Kim KM, Lee YJ, Ko GY, Yoon HK, Sung KB, et al. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2010;17:869-877.
8. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer. 1994;74:2449-2453.
9. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992;31: S1-S6.
10. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Interv Radiol. 2010;33:541-51.
11. Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs. 2011; 22:277-282.
12. Nakao N, Uchida H, Kamino K, Nishimura Y, Ohishi H, Takayasu Y, et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. Cardiovasc Interv Radiol. 1994;17:76-80.
13. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol. 1994;33:S84-S88.
14. Nishimine K, Uchida H, Matsuo N, Sakaguchi H, Hirohashi S, Nishimura Y, et al. Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol. 1994;33:S60-S68.
15. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18: 365-376.
16. Miyayama S, Mitsui T, Zen Y, Sudo Y, Yamashiro M, Okuda M, et al. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res. 2009;39:374-381.
17. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR. 2001;176:681-688.
18. Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, et al. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol. 2008;9:534-540.
19. Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, et al. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol. 2009;15:1843-1848.
20. Takaki S, Sakaguchi H, Anai H, Tanaka T, Yamamoto K, Morimoto K, et al. Long-term outcome of transcatheter subsegmental and segmental arterial chemoembolization using lipiodol for hepatocellular carcinoma. Cardiovasc Interv Radiol. 2011 (Epub ahead of print).
21. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
22. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922.
23. Hatanaka Y, Yamashita Y, Takahashi M, Koga Y, Saito R, Nakashima K, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology. 1995;195:747-752.
24. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol. 1999;28:334-340.
25. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Liver Cancer Study Group of Japan, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469.
26. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, PRECISION V Investigators, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol. 2010;33:41-52.
27. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87-92.